# Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)

> **NCT01854658** · PHASE3 · COMPLETED · sponsor: **Pearl Therapeutics, Inc.** · enrollment: 1615 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease (COPD)

## Interventions

- **DRUG:** GFF MDI (PT003)
- **DRUG:** GP MDI (PT001)
- **DRUG:** FF MDI (PT005)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01854658
- **Lead sponsor:** Pearl Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07
- **Primary completion:** 2015-03
- **Final completion:** 2015-03
- **Target enrollment:** 1615 (ACTUAL)
- **Last updated:** 2017-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01854658

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01854658, "Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01854658. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*